JRSIS Health Care Corporation (JRSS) Fair Value & Analysis
Consumer Cyclical · US · Market cap $2.5M
JRSIS Health Care Corporation
JRSS · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 45 days ago
Fair value updated Jun 26, 2026, revised from $0.0100 to $0.0237 (+137.0%) since Jun 24, 2026. Share price −10.0% over the past month.
Below-average quality, screening 32% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain.
- Quality 32/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 26, 2026.
How to read this chart
60‑month range $0.0060 – $83.00 · the $0.0180 price screens below the $0.0237 fair value. Dashed = 300-day average. As of Jun 26, 2026.
Analysis
JRSIS Health Care Corporation (JRSS) currently trades at $0.0180, while our model-based Fair Value estimate is $0.0237, implying the stock looks roughly 31.7% undervalued today. The Quality Score stands at 32/100 (below-average quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, JRSIS Health Care Corporation generated revenue of $3.5M at a net margin of -14.1%. Revenue declined 55.2% year over year. Fundamentals as of Jun 26, 2026
For context, the median of 10 Consumer Cyclical peers we cover trades at -24% fair-value upside, at 32%, JRSS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Notify me when JRSS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
JRSIS Health Care Corporation develops and produces medical technology and equipment in the People's Republic of China. The company develops and markets a multi-faceted smart environment for the retail distribution of pharmaceutical products by pharmacies, hospitals, and online distributors.
Full company description
JRSIS Health Care Corporation develops and produces medical technology and equipment in the People's Republic of China. The company develops and markets a multi-faceted smart environment for the retail distribution of pharmaceutical products by pharmacies, hospitals, and online distributors. It offers JM-YF-2000 Automatic Medicine Dispenser, which provides intelligent prompts for high-speed facile human-computer interaction to yield prompt dispensing of medications and batch refilling in the user safety environment. The company was founded in 2018 and is based in Yongzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JRSIS Health Care Corporation reported revenue of $320K in FY2025 versus $44.4M in FY2021, a compound −70.9%/yr. Reported net income was $8.8K in FY2025, compounding −74.9%/yr from FY2021.
Watch JRSS: get an alert when its fair value changes →
Peer Group
Specialty Retail · 221 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Retail median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Retail stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Casey's General Stores, Inc CASY | $827.04 | $405.44 | -51% |
| Williams-Sonoma, Inc WSM | $222.84 | $164.16 | -26% |
| Ulta Beauty, Inc ULTA | $479.57 | $488.39 | +2% |
| DICK'S Sporting Goods, Inc DKS | $208.89 | $181.10 | -13% |
| Best Buy Co BBY | $83.98 | $109.12 | +30% |
| China Tourism Group 601888 | ¥52.90 | ¥40.40 | -24% |
| Tractor Supply Company TSCO | $31.01 | $35.52 | +15% |
| Murphy USA Inc MUSA | $618.57 | $423.35 | -32% |
| Five Below, Inc FIVE | $197.71 | $117.29 | -41% |
| Taiwan Mobile Co 3045 | 110.50 TWD | 80.98 TWD | -27% |
Compare JRSIS Health Care Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is JRSIS Health Care Corporation (JRSS) overvalued or undervalued?
What is the fair value of JRSS?
What is the quality score of JRSS?
What is the revenue of JRSIS Health Care Corporation (JRSS)?
What is the net profit margin of JRSS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track JRSIS Health Care Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.